Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2024
Incorporating real option value in valuing innovation: a way forward
10 July 2024 - Considerable progress has been made in defining and measuring the real option value of medical technologies. ...
Posted by Michael Wonder on 09 Dec 2021
Consensus lacking on ‘value’ for new anti-cancer drugs
8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...
Posted by Michael Wonder on 22 Aug 2021
Accelerated approval - an unexpected pathway to value-based pricing?
18 August 2021 - Accelerated approval is an important regulatory pathway that provides early access to treatments for patients with serious ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 03 Dec 2020
The real worth of cancer drugs
1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe ...
Posted by Michael Wonder on 06 Oct 2020
FDA announces all time low rates for FY2021 priority review vouchers
5 October 2020 - The US FDA has announced historic low rates for the fiscal year 2021 fees to use ...
Posted by Michael Wonder on 10 May 2020
COVID-19 raises questions about the value of personalised medicine
8 May 2020 - A group of medical dissenters argues that tailoring treatment to the genetic profiles of individuals, a longstanding ...
Posted by Michael Wonder on 10 Mar 2020
Inappropriate use of progression-free survival in cancer drug approvals
10 March 2020 - New drugs should be judged on overall survival or quality of life, preferably both. ...
Posted by Michael Wonder on 17 Oct 2019
Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines
17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...
Posted by Michael Wonder on 10 Jun 2019
The $2.1 million question: what are the medical, ethical implications of the world's priciest drug?
10 June 2019 - With last month’s FDA approval, Zolgensma became the world’s most expensive medication. ...
Posted by Michael Wonder on 23 Feb 2019
When biotechs get breakthrough therapy status, Mr. Market yawns
23 February 2019 - As a biotech consultant, I’ve heard many CEO’s tell me that a “drumbeat of news” is ...
Posted by Michael Wonder on 19 Dec 2018
Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score
19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...
Posted by Michael Wonder on 05 Nov 2018
Novartis says SMA gene therapy is cost-effective at $4-5 million per patient
5 November 2018 - Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy ...
Posted by Michael Wonder on 01 Jul 2018
FDA allows off-label health care economic discussions. Is there more to come?
29 June 2018 - The Trump administration has issued final guidance that allows drug companies and device makers to provide ...
Posted by Michael Wonder on 13 Jun 2018
AMCP applauds FDA for final guidance on payer and manufacturer communications to improve patient access to emerging therapies
13 June 2018 - The Academy of Managed Care Pharmacy commends the U.S. FDA for issuing final guidance that clarifies ...